Intranasal tuberculosis vaccine - BlueWillow Biologics
Alternative Names: Nanoemulsion adjuvanted intranasal tuberculosis vaccine - BlueWillow BiologicsLatest Information Update: 06 Nov 2020
At a glance
- Originator BlueWillow Biologics
- Class Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 20 Oct 2020 BlueWillow Biologics has patent protection for NanoVaxTM adjuvant technology in USA (BlueWillow Biologics website, October 2020)
- 20 Oct 2020 Preclinical trials in Tuberculosis (Prevention) in USA (Intranasal) before October 2020 (BlueWillow Biologics pipeline, October 2020)